Kodiak Sciences (KOD) Stock Price, News & Analysis

Company Overview

Kodiak Sciences Inc. (NASDAQ: KOD) is a clinical-stage biopharmaceutical company focused on developing medicines for serious retinal diseases. The company’s research is centered on its Antibody Biopolymer Conjugate (ABC) platform, which is designed to combine antibody-based therapies with biopolymer technology to potentially extend the duration of treatment in the eye.

Kodiak’s lead programs have focused on ophthalmic diseases involving abnormal blood-vessel growth or leakage, including wet age-related macular degeneration, diabetic macular edema and retinal vein occlusion. Its principal investigational product, KSI-301, is an anti-VEGF-A therapy designed for longer-lasting activity than conventional treatments. Kodiak has also researched KSI-501, a potential dual-action therapy intended to target both VEGF-A and inflammatory pathways implicated in retinal disease.

Founded in 2009, Kodiak has conducted clinical development activities in the United States and other international markets. The company is led by Victor Perlroth, M.D., who co-founded Kodiak and has served as its chief executive officer. Kodiak’s development programs remain focused on addressing the treatment burden associated with frequent intraocular injections for patients with retinal disorders.

Key Stats

• Today's Range: $79.06 to $88.50
• 50-Day Range: $31.52 to $99.87
• 52-Week Range: $13.95 to $104.00
• Volume: 1.39 million shs
• Average Volume: 3.97 million shs
• Market Capitalization: $5.54 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $104.71
• Consensus Rating: Moderate Buy

Kodiak Sciences Stock Analysis - MarketRank™

Kodiak Sciences scored higher than 81% of companies evaluated by MarketBeat, and ranked 56th out of 870 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Kodiak Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Kodiak Sciences has a consensus price target of $104.71, representing about 18.8% upside from its current price of $88.12.

Amount of Analyst Coverage

Kodiak Sciences has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Kodiak Sciences are expected to decrease in the coming year, from ($3.97) to ($4.14) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Kodiak Sciences is -21.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Kodiak Sciences is -21.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Kodiak Sciences has a P/B Ratio of 29.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

26.83% of the float of Kodiak Sciences has been sold short.

Short Interest Ratio / Days to Cover

Kodiak Sciences has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Kodiak Sciences has recently decreased by 12.15%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Kodiak Sciences does not currently pay a dividend.

Dividend Growth

Kodiak Sciences does not have a long track record of dividend growth.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 0.67

News Sentiment

Kodiak Sciences has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 14 news articles for Kodiak Sciences this week, compared to 5 articles on an average week.

Search Interest

24 people have searched for KOD on MarketBeat in the last 30 days. This is an increase of 700% compared to the previous 30 days.

MarketBeat Follows

12 people have added Kodiak Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 4.3 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $156,986,026.00 in company stock, which represents 2.8346% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Kodiak Sciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $156,986,026.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

44.40% of the stock of Kodiak Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

89.06% of the stock of Kodiak Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/15/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:KOD
• CIK: 1468748
• Web: kodiak.com
• Phone: (650) 281-0850
• Fax: N/A
• Employees: 124
• Year Founded: 2009

Price Target and Rating

• Average Price Target for Kodiak Sciences: $104.71
• High Price Target: $145.00
• Low Price Target: $61.00
• Potential Upside/Downside: +18.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.63
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.19)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$229.97 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -273.23%
• Return on Assets: -85.48%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.49
• Quick Ratio: 2.49

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.97 per share
• Price / Book: 29.67

Miscellaneous

• Outstanding Shares: 62,850,000
• Free Float: 34,944,000
• Market Cap: $5.54 billion
• Optionable: Optionable
• Beta: 2.03